These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 12685917)
1. Dopaminergic deficit and the role of amisulpride in the treatment of mood disorders. Montgomery SA Int Clin Psychopharmacol; 2002 Dec; 17 Suppl 4():S9-15; discussion S16-7. PubMed ID: 12685917 [TBL] [Abstract][Full Text] [Related]
2. Dopaminergic deficit and the role of amisulpride in the treatment of schizophrenia. Kasper S Int Clin Psychopharmacol; 2002 Dec; 17 Suppl 4():S19-26. PubMed ID: 12685918 [TBL] [Abstract][Full Text] [Related]
3. Amisulpride versus amineptine and placebo for the treatment of dysthymia. Boyer P; Lecrubier Y; Stalla-Bourdillon A; Fleurot O Neuropsychobiology; 1999; 39(1):25-32. PubMed ID: 9892856 [TBL] [Abstract][Full Text] [Related]
4. The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia. Pani L; Gessa GL Mol Psychiatry; 2002; 7(3):247-53. PubMed ID: 11920152 [TBL] [Abstract][Full Text] [Related]
5. Faster response on amisulpride 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: a randomized, double-blind, parallel group study. Amore M; Jori MC; Int Clin Psychopharmacol; 2001 Nov; 16(6):317-24. PubMed ID: 11712619 [TBL] [Abstract][Full Text] [Related]
6. Focus on amisulpride. Green B Curr Med Res Opin; 2002; 18(3):113-7. PubMed ID: 12094819 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of antidepressants for dysthymia: a meta-analysis of placebo-controlled randomized trials. Levkovitz Y; Tedeschini E; Papakostas GI J Clin Psychiatry; 2011 Apr; 72(4):509-14. PubMed ID: 21527126 [TBL] [Abstract][Full Text] [Related]
8. Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group. Lecrubier Y; Boyer P; Turjanski S; Rein W J Affect Disord; 1997 Apr; 43(2):95-103. PubMed ID: 9165379 [TBL] [Abstract][Full Text] [Related]
9. Amisulpride in medium-term treatment of dysthymia: a six-month, double-blind safety study versus amitriptyline. AMILONG investigators. Ravizza L J Psychopharmacol; 1999; 13(3):248-54. PubMed ID: 10512080 [TBL] [Abstract][Full Text] [Related]
10. Combination therapy with amisulpride and antidepressants: clinical observations in case series of elderly patients with psychotic depression. Politis AM; Papadimitriou GN; Theleritis CG; Psarros C; Soldatos CR Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jul; 32(5):1227-30. PubMed ID: 18442877 [TBL] [Abstract][Full Text] [Related]
11. An open-label pilot study to evaluate the efficacy of sildenafil citrate in middle-aged men with late-onset dysthymia. Orr G; Seidman SN; Weiser M; Gershon AA; Dubrov Y; Klein DF J Nerv Ment Dis; 2008 Jun; 196(6):496-500. PubMed ID: 18552628 [TBL] [Abstract][Full Text] [Related]
12. Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial. Kim SW; Shin IS; Kim JM; Lee SH; Lee JH; Yoon BH; Yang SJ; Hwang MY; Yoon JS Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1504-9. PubMed ID: 17692448 [TBL] [Abstract][Full Text] [Related]
13. Consensus on the use of substituted benzamides in psychiatric patients. Racagni G; Canonico PL; Ravizza L; Pani L; Amore M Neuropsychobiology; 2004; 50(2):134-43. PubMed ID: 15292667 [TBL] [Abstract][Full Text] [Related]
14. A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Rosenzweig P; Canal M; Patat A; Bergougnan L; Zieleniuk I; Bianchetti G Hum Psychopharmacol; 2002 Jan; 17(1):1-13. PubMed ID: 12404702 [TBL] [Abstract][Full Text] [Related]
15. A double-blind, randomised, controlled clinical trial of acetyl-L-carnitine vs. amisulpride in the treatment of dysthymia. Zanardi R; Smeraldi E Eur Neuropsychopharmacol; 2006 May; 16(4):281-7. PubMed ID: 16316746 [TBL] [Abstract][Full Text] [Related]
16. Duloxetine in the treatment of major psychiatric and neuropathic disorders. Müller N; Schennach R; Riedel M; Möller HJ Expert Rev Neurother; 2008 Apr; 8(4):527-36. PubMed ID: 18416656 [TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression. Cowen PJ; Ogilvie AD; Gama J Curr Med Res Opin; 2005 Mar; 21(3):345-56. PubMed ID: 15811202 [TBL] [Abstract][Full Text] [Related]
18. Natural killer cell cytotoxity and course of illness in depressed mood. Reynaert C; Janne P; Jacques D; Tordeurs D; Zdanowicz N Psychiatr Danub; 2010 Nov; 22 Suppl 1():S132-4. PubMed ID: 21057421 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness of psychotherapy and combination treatment for chronic depression. Arnow BA; Constantino MJ J Clin Psychol; 2003 Aug; 59(8):893-905. PubMed ID: 12858430 [TBL] [Abstract][Full Text] [Related]
20. The efficacy of drug treatments for dysthymia: a systematic review and meta-analysis. de Lima MS; Hotoph M; Wessely S Psychol Med; 1999 Nov; 29(6):1273-89. PubMed ID: 10616934 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]